The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Results of a phase I/II clinical trial of BPX-101, a novel drug-activated dendritic cell (DC) vaccine for metastatic castration-resistant prostate cancer (mCRPC).
Guru Sonpavde
No relevant relationships to disclose
John D. McMannis
No relevant relationships to disclose
Yu Bai
No relevant relationships to disclose
Mamatha Seethammagari
No relevant relationships to disclose
Joan Marie C. Bull
No relevant relationships to disclose
Victoria Hawkins
No relevant relationships to disclose
Theresa Dancsak
No relevant relationships to disclose
Natalia Lapteva
No relevant relationships to disclose
David M. Spencer
No relevant relationships to disclose
Kevin M. Slawin
No relevant relationships to disclose